
    
      This study will evaluate the safety, tolerability, pharmacokinetics, metabolites,
      pharmacodynamics, and clinical activity of MRTX849 with Pembrolizumab in Patients with
      Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation.

      MRTX849 is an orally available small molecule inhibitor of KRAS G12C, and

      Pembrolizumab (KEYTRUDAÂ®) is a humanized monoclonal antibody that blocks the interaction
      between PD-1 and its ligands, PD-L1 and PD-L2.
    
  